Annual Meeting 2014: Results of Myeloma XI, a phase III trial comparing different IMiDs

Charlotte Pawlyn, MD
Institute of Cancer Research
Sutton, United Kingdom

Treatment with immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) has dramatically increased response rates and survival for myeloma patients over the last decade. Triplet drug combinations are more effective than doublets or single agents. The more recently developed IMiD lenalidomide, with a different spectrum of effects to thalidomide, is an excellent option for induction therapy due to its oral administration and lack of significant peripheral neuropathy (PN) when compared with bortezomib and thalidomide.

Visit our website at: http://www.myeloma.org